Study analysis · Asia Pacific journal of clinical nutrition · 2006
Fish oil pills won't reduce inflammation — even when they raise omega-3 levels in your blood.
Taking tiny fish oil or mussel oil pills for six weeks raised some good fats in your blood but didn't calm down any inflammation.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave two kinds of fish oil to 30 healthy people and checked if their inflammation went down. It found no change in inflammation, but did find a small increase in some good fats. We can say the oil didn't reduce inflammation in these people, but we can't say it will work the same for everyone.
What’s the bottom line?
People took small daily doses of fish oil or mussel oil for six weeks to see if it calmed down body inflammation.
How strong is this study?
This study was well-designed because people didn't know which oil they got, and they were randomly assigned — that helps avoid bias. But it only had 30 people, so we can't be super sure the results apply to everyone. Bigger studies with sicker people would be needed to trust it more.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
78 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=30)+2.8/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The abstract explicitly states the study is a double-blind, randomized, parallel intervention trial with a control group, which allows for causal inference. However, the small sample size (n=30) and focus on healthy individuals limit the strength and generalizability of causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study describes a double-blind, randomized trial with clear methodology, but no conflict of interest statement or funding disclosure was provided. This absence limits transparency but does not, by itself, indicate bias.
Key takeaways
- 01
Both oils raised EPA in blood cells by 15–20%; mussel oil also raised DHA; none of the inflammation markers (like PGE2 or TNF-alpha) went down.
- 02
Even though blood fats changed, the body didn't show less inflammation — so these tiny doses didn't help reduce inflammation in healthy people.
Surprising findings
- Neutrophil EPA increased significantly, but inflammatory markers like PGE2 and TNF-alpha showed no change.It’s widely believed that raising omega-3 levels in blood cells should reduce inflammation — this study directly contradicts that assumption at low doses.
Practical takeaways
If you're taking omega-3s for inflammation, consider whether your dose is high enough — this study used less than 200 mg/day.
This study only tested one low dose over six weeks in healthy people; results may differ in chronic inflammation or higher doses.
low confidenceWhy this study matters
EPA Rises, But Inflammation Doesn't Drop
Both fish oil and mussel oil increased neutrophil eicosapentaenoic acid (EPA) by 15–20% after six weeks, yet not a single inflammatory marker — including prostaglandin E2, TNF-alpha, IL-1 beta, or thromboxane B2 — decreased.
People take omega-3s hoping to reduce inflammation, but this study shows that even when the blood levels go up, the body doesn't respond with less inflammation — at least at this low dose.
Mussel Oil Beats Fish Oil at One Thing
Only the green-lipped mussel oil group saw a significant increase in docosahexaenoic acid (DHA), while fish oil did not — despite both providing similar total omega-3 doses (173–241 mg/day).
If you're choosing supplements for DHA (brain/eye health), this suggests mussel oil might have an edge — but only if you're okay with a less-studied source.
The Dose Might Be Too Low
Participants consumed only 173–199 mg/day of omega-3s total — including their diet — far below the 1,000–2,000 mg/day often recommended for anti-inflammatory effects.
This study doesn’t prove omega-3s don’t work — it proves this tiny dose doesn’t. Many people assume all omega-3 supplements are equal, but dose matters.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
People took small daily doses of fish oil or mussel oil for six weeks to see if it calmed down body inflammation.
Research results
Both oils raised EPA in blood cells by 15–20%; mussel oil also raised DHA; none of the inflammation markers (like PGE2 or TNF-alpha) went down.
What this means - more context
Even though blood fats changed, the body didn't show less inflammation — so these tiny doses didn't help reduce inflammation in healthy people.
This study aimed to compare the effects of low-dose marine oil supplementation from fish and green-lipped mussel sources on inflammatory markers in healthy adults.
Six weeks of low-dose omega-3 supplementation (173–199 mg/day) from fish or mussel oil increased neutrophil eicosapentaenoic acid in both groups and docosahexaenoic acid only in the mussel group, but did not reduce serum thromboxane B2, monocyte prostaglandin E2, interleukin-1 beta, or tumor necrosis factor alpha.
Methods Used
Double-blind, randomized, parallel intervention study with 30 healthy adults; participants consumed 2 mL/day of fish oil (181 mg n-3 LCPUFA) or green-lipped mussel oil (241 mg n-3 LCPUFA) for six weeks; baseline diet provided ~73 mg/day n-3 LCPUFA; measured neutrophil phospholipid fatty acids and serum/inflammatory markers.
Main Finding
Low-dose marine oil supplementation increased neutrophil eicosapentaenoic acid by 15–20% and docosahexaenoic acid only with mussel oil, but did not significantly change serum thromboxane B2, prostaglandin E2, interleukin-1 beta, or tumor necrosis factor alpha.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect sizes not reported in abstract
- •Small sample size (n=30) with no subgroup analysis reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Neutrophil EPA increased significantly, but inflammatory markers like PGE2 and TNF-alpha showed no change.
It’s widely believed that raising omega-3 levels in blood cells should reduce inflammation — this study directly contradicts that assumption at low doses.
Practical Takeaways
If you're taking omega-3s for inflammation, consider whether your dose is high enough — this study used less than 200 mg/day.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave two kinds of fish oil to 30 healthy people and checked if their inflammation went down. It found no change in inflammation, but did find a small increase in some good fats. We can say the oil didn't reduce inflammation in these people, but we can't say it will work the same for everyone.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Explicitly described as double-blind, randomized, parallel-group RCT
- Clear intervention details (doses, duration, control group)
- Objective biomarker outcomes measured
Weaknesses
- Small sample size (n=30)
- Only healthy participants — limits applicability to clinical populations
- Full methodology not available — based on abstract only
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
People took small daily doses of fish oil or mussel oil for six weeks to see if it calmed down body inflammation.
Research results
Both oils raised EPA in blood cells by 15–20%; mussel oil also raised DHA; none of the inflammation markers (like PGE2 or TNF-alpha) went down.
What this means - more context
Even though blood fats changed, the body didn't show less inflammation — so these tiny doses didn't help reduce inflammation in healthy people.
This study aimed to compare the effects of low-dose marine oil supplementation from fish and green-lipped mussel sources on inflammatory markers in healthy adults.
Six weeks of low-dose omega-3 supplementation (173–199 mg/day) from fish or mussel oil increased neutrophil eicosapentaenoic acid in both groups and docosahexaenoic acid only in the mussel group, but did not reduce serum thromboxane B2, monocyte prostaglandin E2, interleukin-1 beta, or tumor necrosis factor alpha.
Methods Used
Double-blind, randomized, parallel intervention study with 30 healthy adults; participants consumed 2 mL/day of fish oil (181 mg n-3 LCPUFA) or green-lipped mussel oil (241 mg n-3 LCPUFA) for six weeks; baseline diet provided ~73 mg/day n-3 LCPUFA; measured neutrophil phospholipid fatty acids and serum/inflammatory markers.
Main Finding
Low-dose marine oil supplementation increased neutrophil eicosapentaenoic acid by 15–20% and docosahexaenoic acid only with mussel oil, but did not significantly change serum thromboxane B2, prostaglandin E2, interleukin-1 beta, or tumor necrosis factor alpha.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect sizes not reported in abstract
- •Small sample size (n=30) with no subgroup analysis reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Neutrophil EPA increased significantly, but inflammatory markers like PGE2 and TNF-alpha showed no change.
It’s widely believed that raising omega-3 levels in blood cells should reduce inflammation — this study directly contradicts that assumption at low doses.
Practical Takeaways
If you're taking omega-3s for inflammation, consider whether your dose is high enough — this study used less than 200 mg/day.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave two kinds of fish oil to 30 healthy people and checked if their inflammation went down. It found no change in inflammation, but did find a small increase in some good fats. We can say the oil didn't reduce inflammation in these people, but we can't say it will work the same for everyone.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Explicitly described as double-blind, randomized, parallel-group RCT
- Clear intervention details (doses, duration, control group)
- Objective biomarker outcomes measured
Weaknesses
- Small sample size (n=30)
- Only healthy participants — limits applicability to clinical populations
- Full methodology not available — based on abstract only
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was well-designed because people didn't know which oil they got, and they were randomly assigned — that helps avoid bias. But it only had 30 people, so we can't be super sure the results apply to everyone. Bigger studies with sicker people would be needed to trust it more.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
78 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=30)+2.8/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The abstract explicitly states the study is a double-blind, randomized, parallel intervention trial with a control group, which allows for causal inference. However, the small sample size (n=30) and focus on healthy individuals limit the strength and generalizability of causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study describes a double-blind, randomized trial with clear methodology, but no conflict of interest statement or funding disclosure was provided. This absence limits transparency but does not, by itself, indicate bias.